School of Medicine - Clinical MedicineHepatology




The Clinical Department of Hepatology was established in 2011 at Kanazawa Medical University Hospital and the Department of Hepatology was established in the School of Medicine in September, 2016.
In clinical practice, we concentrate on treating patients with hepatobiliary and pancreatic diseases (HBPD), as well as other gastrointestinal disorders. In particular, we focus on antiviral therapy for hepatitis B and C patients. For treatment of hepatocellular carcinoma (HCC), we perform radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) in collaboration with the Department of Radiology. We employ endoscopy to treat pancreatic cancer and biliary tract diseases such as cholelithiasis.
Our research focuses on elucidating the mechanisms of the pathogenesis of alcoholic and non-alcoholic liver diseases. We also focus on the prevention of hepatic ischemia and reperfusion injury. In addition, we are collaborating with the Medical Research Institute and Regenerative Medicine Center on the theme of liver regeneration employing hepatic stem cells.
In education, we do our best to provide the latest information in lectures and train our students in Bed Side Learning and Clinical Clerkship. We also provide individual tutoring to final year students to prepare for the National Medical Practitioners Qualifying Examination. In postgraduate medical education, we teach various procedures and educate residents on the necessary knowledge and skills for diagnosis and treatment.
In order to make our department vibrant and active, all our members are working hard in education, treatment, and research.

Contact Information

TEL: 076-218-8396 +81-76-218-8396 / FAX: 076-218-8459 +81-76-218-8459 / Email:


Professor and Chair

  • TSUTSUMI Mikihiro



Associate Professor

  • TOSHIKUNI Nobuyuki
  • OZAKI Kazuaki

Senior Assistant Professor

  • JOSEPH George
  • FUKUMURA Atsushi
  • HAYASHI Nobuhiko
  • SAITO Takashi

Assistant Professor

  • MINATO Takashiro
  • MATSUE Yasuhiro

Research Achievements

Research Activities

  • GGsTop, a novel and specific γ-glutamyl transpeptidase inhibitor, protects hepatic ischemia-reperfusion injury in rats.
    Tamura K, Hayashi N, George J, Toshikuni N, Arisawa T, Hiratake J, Tsuchishima M, Tsutsumi M.
    Am J Physiol Gastrointest Liver Physiol. 2016 Aug 1; 311(2): G305-12.
  • Elevated Serum Gamma-glutamyl Transpeptidase Levels and Fatty Liver Strongly Predict the Presence of Carotid Plaque.
    Toshikuni N, Asaji T, Nakanishi Y, Nagasawa SY, Uenishi H, Tsutsumi M.
    J Atheroscler Thromb. 2015; 22(10): 1051-60.
  • Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.
    Matsue Y, Tsutsumi M, Hayashi N, Saito T, Tsuchishima M, Toshikuni N, Arisawa T, George J.
    PLOS ONE. e0118744. 2015.
  • Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis.
    Minato T, Tsutsumi M, Tsuchishima M, Hayashi N, Saito T, Matsue Y, Toshikuni N, Arisawa T, George J.
    Mol Med. 10: 490-502. 2014.
  • Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease.
    N.Hayashi, J.George, M.Takeuchi, A.Fukumura, N.Toshikuni, T.Arisawa. M.Tsutsumi
    PLOS ONE. 8. e70034. 2013.

External Research Funding